Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 16

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
Item 1. Condensed Consolidated Financial Statements (Unaudited)

2

Table of Contents

Crinetics Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

September 30,2025December 31,2024(Unaudited)ASSETSCURRENT ASSETSCash and cash equivalents$110,901 $264,545 Restricted cash500 500 Investment securities, amortized cost of $979,147 at September 30, 2025 and $1,088,561 at December 31, 2024981,390 1,089,524 Prepaid expenses and other current assets28,484 20,819 Total current assets1,121,275 1,375,388 Property and equipment, net14,377 12,068 Operating lease right-of-use assets41,147 43,507 Restricted cash, net of current portion800 800 Prepaid expenses and other assets, net of current portion18,432 2,829 TOTAL ASSETS$1,196,031 $1,434,592 LIABILITIES AND STOCKHOLDERS’ EQUITYCURRENT LIABILITIESAccounts payable and accrued expenses$33,674 $21,469 Accrued compensation and related expenses32,398 28,887 Deferred revenue1,642 2,176 Operating lease liabilities6,441 7,152 Total current liabilities74,155 59,684 Operating lease liabilities, non-current42,703 44,570 Deferred revenue, non-current4,110 4,704 Other liabilities2,894 829 TOTAL LIABILITIES123,862 109,787 Commitments and contingencies (Note 6)STOCKHOLDERS’ EQUITYPreferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at September 30, 2025 or December 31, 2024— — Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 94,548 shares issued and outstanding at September 30, 2025; 92,926 shares issued and outstanding at December 31, 20242,364,699 2,275,952 Accumulated other comprehensive income2,194 963 Accumulated deficit(1,294,612)(952,110)Stock